Pneumococcal polysaccharide vaccine: A systematic review of clinical effectiveness in adults

L. Watson, B.J. Wilson, N. Waugh

Research output: Contribution to journalArticlepeer-review

116 Citations (Scopus)

Abstract

Pneumococcal polysaccharide vaccine is recommended in western countries for individuals at high risk of pneumococcal illness. We undertook a systematic review of randomised controlled trials of pneumococcal vaccine in adults, to determine the effects on clinical outcomes. Results: In industrialised populations, no benefit was detected for outcomes other than pneumococcal bacteraemia, and this did not reach statistical significance. In non-industrial populations, clear benefit was demonstrated for mortality and all-cause pneumonia. Conclusion: Benefit from pneumococcal vaccination depends on the baseline risk of infection and characteristics of a given population. Evidence from randomised trials for widespread adult vaccination in industrial countries is lacking. © 2002 Elsevier Science Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)2166-2173
Number of pages8
JournalVaccine
Volume20
Issue number17-18
DOIs
Publication statusPublished - 2002

Fingerprint

Dive into the research topics of 'Pneumococcal polysaccharide vaccine: A systematic review of clinical effectiveness in adults'. Together they form a unique fingerprint.

Cite this